Severe autoimmunity after checkpoint inhibitor therapy in a patient with autoimmune polyglandular syndrome type 1
Alexandra Lim, Esther M Peluso, Ian A Downs, Brian H Horwich, Maria A Velez-Velez, Melissa G Lechner · 2026
Read Severe autoimmunity after checkpoint inhibitor therapy in a patient with autoimmune polyglandular syndrome type 1 by Alexandra Lim, Esther M Peluso, Ian A Downs, Brian H Horwich, Maria A Velez-Velez, Melissa G Lechner (2026) in the Tower of Babel, a free online library of public-domain works preserved in clean, searchable text. No sign-up. The full text is served as a plain-text file at a predictable URL, where text is present: https://antarctic-labs.com/tower-of-babel/pmc-13247532.txt.
Description
Lim, Peluso, and Downs report a hard lesson about cancer immunotherapy in this 2026 JCEM Case Reports article. Their patient had autoimmune polyglandular syndrome type 1, an inherited failure of immune tolerance caused by a faulty AIRE gene. She received checkpoint inhibitor drugs for a squamous cell cancer of the hard palate, treatment that releases the immune system's brakes and can provoke autoimmune attacks even in ordinary patients.
She developed three such attacks at once: immune hepatitis, thyroiditis, and new diabetes. Doctors treated her with immune suppressants, thyroid hormone, and insulin. The authors use the case to argue for careful screening for hidden autoimmunity before checkpoint therapy, proposing a two-hit model: weak central tolerance plus released immune brakes invites multiple, severe autoimmune complications.
Catalog record
| CREATOR | Alexandra Lim, Esther M Peluso, Ian A Downs, Brian H Horwich, Maria A Velez-Velez, Melissa G Lechner |
|---|---|
| YEAR | 2026 |
| COLLECTION | PAPERS |
| FORMAT | TXT |
| FILE SIZE | 18 KB |
| VERSION | 1.0 |
| LICENSE | CC BY 4.0 |
| RIGHTS | CC BY |
| SOURCE | Europe PMC |